US 12,220,415 B2
WEE1 kinase inhibitors and methods of treating cancer using the same
Philip Reigan, Denver, CO (US); Donald S. Backos, Aurora, CO (US); Christopher J. Matheson, Denver, CO (US); and Kimberly A. Casalvieri, Denver, CO (US)
Assigned to The Regents of the University of Colorado, A Body Corporate, Denver, CO (US)
Appl. No. 16/975,818
Filed by The Regents of the University of Colorado, A Body Corporate, Denver, CO (US)
PCT Filed Feb. 28, 2019, PCT No. PCT/US2019/019936
§ 371(c)(1), (2) Date Aug. 26, 2020,
PCT Pub. No. WO2019/169065, PCT Pub. Date Sep. 6, 2019.
Claims priority of provisional application 62/636,831, filed on Feb. 28, 2018.
Prior Publication US 2020/0405723 A1, Dec. 31, 2020
Int. Cl. A61K 31/519 (2006.01); A61K 31/635 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61P 35/02 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/635 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61P 35/02 (2018.01)] 15 Claims
 
1. A compound having the chemical structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is 3-(2-hydroxypropan-2-yl) phenyl or 6-(2-hydroxypropan-2-yl) pyridin-2-yl;
R2 is allyl, methyl, ethyl, propyl, isopropyl, butyl, or isobutyl;
R3 is O;
R4 is NR7R8;
R7 and R8 each are independently H or 4-(2 (dimethylamino) ethyl) phenyl); and wherein
R7 and R8 are not simultaneously H.